DHRHealthcare · Diagnostics & ResearchThe 24 Wall Street analysts covering Danaher Corp. hold a median 12-month price target of $260 — +14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 5 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Danaher Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (94): The share price has been relatively steady.
Accruals (40): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.9% from it.
Of the 20 most recent actions, 12 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | Baird | Maintains | Outperform | $246 → $254 |
| 22 Oct 2026 | Barclays | Maintains | Overweight | $255 → $260 |
| 22 Oct 2026 | Citigroup | Maintains | Buy | $230 → $270 |
| 22 Oct 2026 | JP Morgan | Maintains | Overweight | $250 → $270 |
| 22 Oct 2026 | Stifel | Maintains | Buy | $220 → $260 |
| 22 Oct 2026 | TD Cowen | Maintains | Buy | $255 → $270 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $220 → $240 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | — |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | — |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $236 → $255 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | — |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $230 → $255 |
| 5 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 5 Oct 2026 | RBC Capital | Maintains | Outperform | $215 → $250 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $200 → $250 |
| 22 July 2026 | Guggenheim | Maintains | Buy | — |
| 22 July 2026 | Guggenheim | Maintains | Buy | $235 → $200 |
| 22 July 2026 | RBC Capital | Maintains | Outperform | $200 → $215 |
| 22 July 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DHR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Nov 2026, Danaher Corp. returned +7.4% against +9.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 19% of US stocks
Cheaper than 30% of US stocks
Cheaper than 12% of US stocks
Higher than 49% of US stocks
Higher than 70% of US stocks
Higher than 71% of US stocks
Higher than 80% of US stocks
Higher than 79% of US stocks
Higher than 59% of US stocks
Higher than 71% of US stocks
Higher than 67% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Danaher Corp. has a market value of $159.1B and an enterprise value of $187.4B.
Revenue in the twelve months to 30 June 2026: $25.1B. The latest quarter grew 8.3% year on year.
Net income over the same four quarters: $4.0B, a 15.9% net margin.
Diluted earnings per share, trailing twelve months: $5.63.
Free cash flow in the twelve months to 30 June 2026: $5.5B, after $1.1B of capital spending.
Danaher Corp. spent $2.9B on share buybacks and $964.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 37.5×; forward P/E: 24.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.71%, paying out 25% of earnings.
Danaher Corp. employs 58,000 people — $433K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Danaher Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Danaher announced that President and CEO Julie Sawyer Montgomery will present at the UBS Global Healthcare Conference on November 9, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026.
Why it matters — DHR watchers can note the scheduled appearances by the company’s CEO at two healthcare investor conferences.
Danaher (DHR) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.
Why it matters — DHR watchers may note the upgrade as an indicator of increased optimism about the company’s earnings prospects.
A Zacks Investment Research headline compares Labcorp Holdings (LH) and Danaher (DHR) for investors considering value stocks. The excerpt poses which company may be more attractive to value investors but provides no conclusion.
Why it matters — DHR watchers may find the comparison relevant when assessing Danaher alongside Labcorp as a medical services stock.
Danaher reported Q3 revenue growth of 8.3% year over year to $6.55 billion and adjusted EPS of $2.11, with strong segment growth, particularly in Diagnostics. The recap also noted respiratory revenue volatility and pricing pressure from China's volume-based procurement.
Why it matters — DHR watchers may weigh the reported performance and Diagnostics growth against the cited revenue and pricing headwinds.
Danaher beat analyst estimates for revenue and profitability, and its full-year earnings guidance exceeded consensus expectations.
Why it matters — These results and guidance are relevant to DHR watchers assessing the company’s performance and outlook.
The 24 Wall Street analysts covering Danaher Corp. have a median 12-month price target of $260, with estimates ranging from $220 to $310. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Danaher Corp., 20 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Danaher Corp. 73 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Nov 2026, Danaher Corp. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +14.9% from the last close, and Ticker Nerd's factor model ranks Danaher Corp. 73 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Danaher Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $220 to $310 over the next 12 months.
Danaher Corp. returned +7.4% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics.
The most recent item we track (PRNewsWire, 2 Nov 2026): "Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences". Danaher announced that President and CEO Julie Sawyer Montgomery will present at the UBS Global Healthcare Conference on November 9, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026.
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. Its current business is organized around Biotechnology, Life Sciences, and Diagnostics, with offerings that support areas such as biologics manufacturing, molecular and clinical diagnostics, genomics, and analytical instrumentation. Danaher serves customers across healthcare, research, and industrial settings, helping laboratories and life sciences organizations improve efficiency, precision, and productivity. Headquartered in Washington, D.C., Danaher operates through a portfolio of specialized operating companies that provide products and solutions for scientific discovery, disease detection, and the production of biologic therapies.
CEO Ms. Julie Sawyer Montgomery · 58,000 employees · United States · https://www.danaher.com
